LB Pharma Files $200M ATM and Registers 8.5M PIPE Shares for Resale
LBRX has more than doubled off its 52-week low of $14.317.
Summary
LB Pharmaceuticals filed a shelf registration launching a $200M ATM program with TD Cowen and registering 8.49M PIPE shares for resale, adding significant potential dilution and selling pressure.
Key Events · Financing and Capital Events · LBRX
-
$200M ATM Program Launched
LB Pharmaceuticals entered a Sales Agreement with TD Cowen to sell up to $200M of common stock from time to time at market prices, with TD Cowen earning up to 3.0% commission on gross proceeds.
-
8.49M PIPE Shares Registered for Resale
The filing registers 8,489,673 shares for resale by selling stockholders from the February 2026 and July 2026 PIPEs, including 2,132,620 shares underlying pre-funded warrants.
-
Dilution Impact
At the assumed $38.38 offering price, selling 5,211,047 ATM shares would increase shares outstanding from 28.68M to 33.89M — roughly 18% dilution to existing holders.
-
Prior S-1 Replaced
This S-3ASR replaces the prior S-1 (File No. 333-294900) and carries forward 4,196,600 unsold resale shares, consolidating all PIPE resale registrations into one shelf.
Analysis · LBRX · Life Sciences
A new S-3ASR filing from LB Pharmaceuticals launches a $200 million at-the-market offering with TD Cowen and registers 8.49 million shares held by PIPE investors for resale. The ATM provides a flexible equity line to fund the Phase 3 NOVA-2 schizophrenia trial, but it also creates a persistent overhang on the stock. The resale registration makes shares from the February and July 2026 private placements freely tradable, meaning large institutional holders like Deep Track Capital and Commodore Capital can now exit positions. This comes after a $150M July PIPE and a wider Q2 loss of $51.6M, so the company is clearly prioritizing liquidity runway over near-term shareholder dilution concerns.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LBRX was trading at $37.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $14.32 to $50.16. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.